Kristen Stidham
Associate
Kristen Stidham is an associate in the employee benefits and compensation practice at Wilson Sonsini Goodrich & Rosati. She focuses on the representation of private and public technology and growth companies with respect to executive compensation and employee benefits matters, particularly in mergers and acquisitions, capital markets transactions, and corporate governance and compliance matters.
Experience
Kristen Stidham is an associate in the employee benefits and compensation practice at Wilson Sonsini Goodrich & Rosati. She focuses on the representation of private and public technology and growth companies with respect to executive compensation and employee benefits matters, particularly in mergers and acquisitions, capital markets transactions, and corporate governance and compliance matters.
Education
- J.D., Cornell Law School, 2020Concentration in Business Law and Regulation
- B.A., Program of Liberal Studies, University of Notre Dame, 2016
Admissions
- State Bar of California
Credentials
Education
- J.D., Cornell Law School, 2020Concentration in Business Law and Regulation
- B.A., Program of Liberal Studies, University of Notre Dame, 2016
Admissions
- State Bar of California
Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises SpyGlass Pharma on $150 Million IPO
On February 5, 2026, SpyGlass Pharma, Inc., a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by SpyGlass Pharma, are expected to be approximately $150 million. Wilson Sonsini Goodrich & Rosati advised SpyGlass Pharma on the transaction.
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes:
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes:
Learn More
Client Highlights
Wilson Sonsini Advises Foresight Diagnostics on Acquisition by Natera
On December 5, 2025, Natera, Inc., a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, announced that Natera has completed its acquisition of Foresight in an all-stock transaction consisting of a $275 million upfront payment with an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones. Wilson Sonsini Goodrich & Rosati advised Foresight on the transaction.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
Learn More
Recent Events
WSGR Events
Executive Compensation Insights for Private and Public Companies
Join Wilson Sonsini alumni and friends for a luncheon and hear from Brandon Gantus, co-leader of the firm’s employee benefits and compensation group, and Ralph Barry, principal at Compensia, on some recent trends in executive compensation for private and public companies. The discussion will be moderated by Kristen Stidham, an associate in the firm’s employee benefits and compensation group.
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.